Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Independent Janoshik verification with every order
Cart
Your cart is empty
Find
Valtrax Research is opening — leave your email and we'll ping you the moment the first compounds are listed.
Your cart is empty
Pentapeptide secretagogue · selective at GHS-R1a
A selective growth hormone secretagogue and ghrelin receptor agonist pentapeptide. Supplied as a lyophilized powder for research purposes only.
Catalog opens shortly. Leave your address and we will ping you the moment this compound is orderable.
Assayed by Janoshik to ≥99% purity — the certificate is included with every order.
Valtrax Research supplies materials strictly for in-vitro laboratory research. They are not drugs, supplements, cosmetics, or medical devices, and are not intended for human or animal use, ingestion, or administration. By ordering, you confirm you are a qualified researcher purchasing for lawful research use, in accordance with all applicable Canadian laws and regulations.
Aib-His-D-2Nal-D-Phe-Lys — five residues, with the non-natural Aib and the two D-amino acids carrying the load that keeps it intact. Ipamorelin is a growth-hormone secretagogue: it agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs to trigger GH release, copying ghrelin’s GH effect while leaving ghrelin’s appetite drive behind.
Its standing rests on a negative result. Raun’s founding work showed it raised GH cleanly, with no cortisol or prolactin spillover of the kind that compromised earlier secretagogues — and that clean profile is exactly why it endures as a reference GHS on the bench.
Selectivity is the finding the literature keeps returning to — GH release with little to no movement in cortisol or prolactin, established by Raun and treated since as ipamorelin’s signature. Built around it are the GH/IGF-1 output measurements, Johansen’s rat bone-growth line, and PK/PD modeling that ties stimulus to response.
Ipamorelin serves as a clean probe of the ghrelin-receptor branch of GH control. Bound to GHS-R1a on somatotrophs, it drives growth-hormone release; because its selectivity for that receptor is high, the GH signal arrives largely decoupled from the rest of the pituitary output.
That decoupling is the utility. Ghrelin itself drags appetite and wider endocrine effects into any experiment, whereas ipamorelin lets a lab ask the narrower question — what the GHS-R1a signal on its own does to GH, and through GH to IGF-1.
Ipamorelin emerged from a targeted program at Novo Nordisk aimed at a growth-hormone secretagogue that would hit the receptor without the off-target activity of the preceding GHRP-class peptides. Raun’s 1998 report put it forward as the first genuinely selective GHS.
Later work — Johansen’s longitudinal bone-growth study in rats, then PK/PD modeling in human volunteers — rounded out its profile, and the pentapeptide settled in as a standard tool for ghrelin-receptor research.
Raun, K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue.
PubMedJohansen, P.B. et al. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
PubMedGobburu, J.V.S. et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.
PubMedIndependently verified — identity, purity, and net peptide content.
Same Shelf
